Network Structure enhances access to improved Data Potential

R&D software provider ACD/Labs had signed up to the Tetra Partner Network, a platform developed by scientific data cloud company TetraScience,  which aims to help pharma and biopharma to achieve greater insights into acquired data and potentially improved outcomes.

 For decades ACD/Labs has been helping scientists to assemble multi-technique analytical data from major instrument vendors in a single environment. Its Spectrus platform enables digital interpretations stored with chemical context and the expert's annotations to be stored and managed, speeding routine data analysis by automating data marshalling and improving data accessibility and integrity.

 Tetra Data produced by the Partnership's network platform produces vendor-agnostic, liquid and FAIR (Findable, Accessible, Interoperable, Reusable) scientific data that can be searched, accessed and analysed across the pharmaceutical and biopharmaceutical pipelines. Combining this capability with ACD/Labs' characterisation, lead optimisation and interpretation products would enable customers to accelerate workflows and analyse scientific data with more specificity, noted  Simon Meffan-Main, PhD, VP, Tetra Partner Network. "We are thrilled to partner with ACD/Labs, who have a long history of innovating how customers use analytical data analysis in R&D," he added.

 "Solutions from ACD/Labs and TetraScience work to remove the burden of data management from the scientist's workflow and make the IT function more effective," said Graham McGibbon, Director of Strategic Partnerships, ACD/Labs. "We share a common goal of creating unrestricted innovation for scientists and IT departments and are delighted to be part of the Tetra Partner Network."

 "Industry participants of all kinds – global pharmas, biotech startups, informatics providers, CROs, biopharma app companies, and more – recognise that this movement to the Scientific Data Cloud must be driven by vendor-neutral and open partnerships that are deeply data-centric," explained Patrick Grady, CEO of TetraScience. "Biopharma needs to unify and harmonise experimental data in the cloud, in order to fully capitalise on the power of AI and data science. In turn, AI and data science will uncover insights that will accelerate discovery and development of therapeutics that extend and enhance human life. We are thrilled to further extend this network together with ACD/Labs."

More information online